Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells. / Smagina, Anna S.; Kulemzin, Sergey V.; Yusubalieva, Gaukhar M. и др.
в: Biotechnology and Applied Biochemistry, Том 68, № 4, 08.2021, стр. 849-855.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells
AU - Smagina, Anna S.
AU - Kulemzin, Sergey V.
AU - Yusubalieva, Gaukhar M.
AU - Kedrova, Anna G.
AU - Sanzharov, Andrey E.
AU - Ivanov, Yurii V.
AU - Matvienko, Darya A.
AU - Kalsin, Vladimir A.
AU - Gorchakov, Andrey A.
AU - Baklaushev, Vladimir P.
AU - Taranin, Aleksandr V.
N1 - © 2020 International Union of Biochemistry and Molecular Biology, Inc.
PY - 2021/8
Y1 - 2021/8
N2 - Immunotherapy based on adoptive transfer of genetically engineered T- and NK-cells is an area of active ongoing research and has proven highly efficacious for patients with certain B-cell malignancies. Use of NK cells and NK cell lines as carriers of chimeric antigen receptors (CARs) appears particularly promising, as this opens an opportunity for moving the therapy from autologous to the allogeneic (universal) format. This “off-the-shelf” approach is thought to significantly reduce the price of the treatment and make it available to many more patients in need. Yet, the efficacy of CAR-NK cells in vivo presently remains low, and boosting the activity of CAR NK cells via stronger tumor homing, resistance to tumor microenvironment, as well as greater cytotoxicity may translate into improved patient outcomes. Here, we established a derivative of a human NK cell line YT overexpressing a positive regulator of cytotoxicity, VAV1. Activity of YT-VAV1 cells obtained was assayed in vitro against several cancer cell lines and primary patient-derived cancer cells. YT-VAV1 cells outperform parental YT cells in terms of cytotoxicity.
AB - Immunotherapy based on adoptive transfer of genetically engineered T- and NK-cells is an area of active ongoing research and has proven highly efficacious for patients with certain B-cell malignancies. Use of NK cells and NK cell lines as carriers of chimeric antigen receptors (CARs) appears particularly promising, as this opens an opportunity for moving the therapy from autologous to the allogeneic (universal) format. This “off-the-shelf” approach is thought to significantly reduce the price of the treatment and make it available to many more patients in need. Yet, the efficacy of CAR-NK cells in vivo presently remains low, and boosting the activity of CAR NK cells via stronger tumor homing, resistance to tumor microenvironment, as well as greater cytotoxicity may translate into improved patient outcomes. Here, we established a derivative of a human NK cell line YT overexpressing a positive regulator of cytotoxicity, VAV1. Activity of YT-VAV1 cells obtained was assayed in vitro against several cancer cell lines and primary patient-derived cancer cells. YT-VAV1 cells outperform parental YT cells in terms of cytotoxicity.
KW - cell therapy
KW - NK cells
KW - VAV1
KW - YT cells
KW - THERAPY
KW - VAV
KW - CHIMERIC ANTIGEN RECEPTOR
KW - CAR T-CELLS
KW - Caco-2 Cells
KW - Killer Cells, Natural/immunology
KW - PC-3 Cells
KW - Humans
KW - Immunotherapy
KW - HEK293 Cells
KW - Proto-Oncogene Proteins c-vav/genetics
KW - Neoplasms/immunology
KW - Immunity, Cellular
UR - http://www.scopus.com/inward/record.url?scp=85089605389&partnerID=8YFLogxK
U2 - 10.1002/bab.2001
DO - 10.1002/bab.2001
M3 - Article
C2 - 32767384
AN - SCOPUS:85089605389
VL - 68
SP - 849
EP - 855
JO - Biotechnology and Applied Biochemistry
JF - Biotechnology and Applied Biochemistry
SN - 0885-4513
IS - 4
ER -
ID: 25000141